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1. Introduction  
The association between cancers and thrombosis is well known for a long period of time. In 
1865 Armand Trousseau noted for the first time that unexpected or migratory 
thrombophlebitis could be a sign of an undiagnosed visceral malignancy (Trousseau, 1865). 
Some years later it is said that he observed this complication on himself in the context of an 
occult gastric cancer that cased his death (Khorana, 2003).  
The risk of developing thrombosis in cancer patients is considered to be increased 2- 7 fold 
compared with persons without cancer (Bloom et al, 2005; Heit et al, 2004). This risk is 
dependent on many factors. According to the type of tumor, the risk is thought to be the 
highest in tumors of the ovary, pancreas and central nervous system. Also the extent of the 
tumor, the presence of metastasis, age, immobility and the type of therapy increase this risk. 
Surgery for cancers (Rahr & Sørensen, 1992) and chemotherapy (Levine, 1997) are both 
associated with an important risk of venous thrombosis and embolism. In a large case-
control study that included 3220 patients with cancer, it was reported an overall 7 times 
increased risk for venous thrombosis that depend on type of cancer and time since the 
cancer diagnosis. A very high relative risk was found for gastrointestinal, lung and 
hematological malignancies. Advanced stage of disease was associated with a further 
increase in risk (Blom et al, 2005). 
Patients with cancer who develop venous thromboembolism have a poor prognosis than 
those without this vascular complication. The risk of recurrent thromboembolism and death 
from any cause is greater than three fold in patients with cancer compared to those without 
malignancy (Levitan et al, 1999).  
Epidemiological studies looking for the incidence of cancer in patients with thromboembolic 
events found out that in 15-20% of patients, thromboses were associated with malignancy 
(Er & Zacharsky, 2006).  
The association of cancer and thrombosis raises two distinct problems. On one hand, the 
diagnosis of thrombosis in one patient may represent, in some situations, a sign of an occult 
malignancy. On the other hand, a patient with cancer may develop some time, in the 
evolution of his malignant disease, a thromboembolic event, which may worsen his 
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prognostic. That is why, for the clinical practice, the diagnosis of these associated diseases is 
very important.  
2. Epidemiology of thrombosis in pancreatic cancer  
Pancreatic cancer (PC) is known to be associated with a higher incidence of venous 
thromboembolism than other cancers. The first publication that noted the high incidence of 
thrombosis in PC was a postmortem study done in 1938 (Sproul, 1938). Since that, several 
other studies have been conducted and the incidence found ranges from 5% to 60% (Sack et 
al, 1977; Khorana & Fine, 2005).  
In a cohort study of 202 patients with a first diagnosis of pancreas carcinoma the authors 
found that the risk of venous thrombosis is 6-fold increased compared with the general 
population, at a cumulative risk of 10% (Blom et al, 2006). In this study, tumors of the corpus 
and cauda of the pancreas had a 2-3-fold increase risk of venous thrombosis than tumors of 
the caput of the pancreas (Blom et al, 2006). Similar results showing a higher incidence of 
thrombotic events for tumors located in the corpus and cauda of the pancreas were reported 
by other authors (Sproul, 1938; Sack et al, 1977; Bick, 1992; Pinzon et al, 1986).  
In a retrospective single institute study 6,870 patients with pancreatic cancer were evaluated 
for venous and arterial thrombosis. The incidence of all thrombotic events was 19%with 
venous thrombosis accounting for 17%, arterial thrombotic events for 2% and associated 
venous and arterial events in 0.9% of cases. Pulmonary embolism was found in 25% of 
patients with venous thrombosis (Epstein et al, 2010) 
The risk of venous thrombosis increases in the presence of metastases. Blom and colab. 
found a 2-fold increase risk of venous thrombosis in patients with distant metastases, after 
adjusting for age, sex, surgery and chemo- or radiotherapy (Blom et al, 2006).  
The risk of developing thrombosis is further increased with chemotherapy (Heit, 2002; Wall, 
1989) and also with surgical treatment. Patients with PC treated with chemotherapy had a 
4.8-fold increased risk of thrombosis compared to those without chemotherapy. The same 
study showed no significant increase in thrombotic risk patients treated with radiotherapy 
(Blom et al, 2006). 
Patients with malignancies submitted to surgery have at least twice the risk of postoperative 
venous thrombosis and more than 3 times the risk of fatal PE compared with non-cancer 
patients undergoing a similar procedure (Geerts et al, 2004).  
In patients with PC submitted to surgery there was a 4.5-folf increase in the risk of venous 
thrombosis during the postoperative period of 30 days (Blom et al, 2006).  
The incidence of fatal pulmonary embolism was also evaluated. In one study 4 out of 541 
(0.7%) died from pulmonary embolism (Neoptolemos et al, 2001). Concordant results were 
reported in another study that found 2 of 202 patients (1%) with fatal pulmonary embolism 
(Blom et al, 2006). 
3. Pathogenesis of thrombosis in pancreatic cancer 
The mechanisms underlying the association of venous thromboembolism with pancreatic 
cancer are not completely understood. Large and relevant data suggest an implication of 
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coagulation systems and increased angiogenesis. It is considered that activation of 
hemostasis in pancreatic cancer causes thrombosis but also tumor angiogenesis (Browder et 
al, 2000).  
The key molecule in this process seems to be tissue factor (TF), the main physiologic 
initiator of the extrinsic pathway of coagulation (Gouaulthelimann & Josso, 1979; Nemerson, 
1988). TF plays also an important role in angiogenesis (Mechtcheriakova et al, 1999; Zhang 
et al, 1994).  
TF, also called platelet tissue factor, factor III, or CD142 is a protein present 
in subendothelial tissue, platelets, and leukocytes. TF consists of three domains: 
extracellular that binds factor VIIa, transmembrane and intracellular involved in the 
signaling function (Nemerson, 1988). In healthy individuals there are little circulating 
amounts of active TF. In response to specific stimuli such as inflammation, malignant 
processes, its expression increases (Ruf et al, 2000; Wada et al, 1995).  
As an initiator of coagulation, TF binds and activates factor VIIa, resulting in TF-VIIa 
complex which activates factor X leading to the synthesis of thrombin essential in clot 
formation (Gilbert & Arena, 1995). The activity of TF is regulated by several factors. The 
most important is TF pathway inhibitor which is composed of three different domains: the 
first inhibits FVII, the second inhibits FX and the function of the last one is still unknown 
(Broze, 1995; Girard et al, 1989; Echrish et al, 2011). TF pathway inhibitor is secreted by 
endothelial cells.  
The expression of TF can be controlled by epidermal growth factor receptor (Milsom et al, 
2008) and by FX activated. Increased concentrations of FX activated inhibit the synthesis of 
TF (Ettelaie et al, 2007).  
In cancers, TF is present on malignant cells and also on endothelial cells (Rickles et al, 2003). 
Some previous data indicate that TF is expressed in pancreatic malignant cells. It correlated 
with advanced histological stages and with a poor prognosis (Kakkar et al, 1995; Nitori et al, 
2005). In a retrospective study, Khorana and colab. investigated the expression of TF in non 
invasive and invasive pancreatic cancers. They found an increased expression of TF in 77% 
of patients with pancreatic intraepithelial neoplasia and in 91% of patients with intraductal 
papillary mucinous neoplasms, two non invasive precursors of invasive pancreatic cancer. 
They concluded that TF expression is an early event in pancreatic cancer. In patients with 
pancreas resection, TF expression correlated with expression of vascular endothelial growth 
factor (VEGF) and increased neovascularization, suggesting an implication of TF in 
angiogenesis. They found an incidence of thromboembolism of 26.3% in patients with high 
TF expression levels compared to 4.5% in those with low expression of TF, suggesting an 
important role of TF in cancer associated thrombotic complications. (Khorana et al, 2007).  
Angiogenesis has been documented in pancreatic cancer and it was associated with a rapid 
tumor growth and a poor prognosis (Lomberk, 2010).  
The process of angiogenesis represents the formation of new blood vessels from the pre-
existing vascular bed. In cancers angiogenesis contributes to tumor growth (Folkman, 1995).  
Pancreatic cancer seems to be accompanied by an important increase in angiogenesis that is 
linked to the activation of coagulation. Proteins of coagulation are involved in angiogenesis 
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in two different ways, one clotting dependent and the other one clotting independent 
(Echrish et al, 2011). The clotting dependent mechanism is initiated by the activation of TF 
receptors. TF activates then the coagulation cascade that leading to fibrin formation and 
platelet activation (Falanga & Rickles, 1999). Activated platelets release mediators that 
promote angiogenesis such as VEGF, beta fibroblast growth factor (β-FGF) and platelet grows 
factor (PGF) (Palumbo et al, 2000; Echrish et al, 2011). In clotting independent mechanism 
thrombin plays a very important role by inducing the proteolytic cleavage of protease-
activated receptors (PAR) (Traynelis & Trejo, 2007). The activation of PAR stimulates the 
synthesis of factors implicated in angiogenesis such as VEGF (Liu & Mueller, 2006).  
Another mediator that involved in thrombosis and angiogenesis of pancreatic cancer is 
epithelial growth factor receptor (EGFR). An increased expression EGFR was noted in 
pancreatic cancer and correlated with enhanced angiogenesis, tumor growth and 
unfavorable evolution (Yamanaka et al, 1993).  
Microparticles have also been studied in relation with thromboembolism in cancer. 
Microparticles are membrane vesicles released from stimulated or apoptotic cells in normal 
persons but they are also implicated in the activation of coagulation (Diamant et al, 2004).  
Many recent data support the role of microparticles (MP) and of TF-MP complex in 
thrombotic complications of patients with malignancies (Tilley et al, 2008).  
The level of TF activity associated with TF/MP seems to be higher in PC compared with 
other types of cancer. From the group of patients with cancer and thrombosis those with 
pancreatic malignancies have the highest TF activity (Tesselaar et al, 2009).  
The role of P-selectin in thrombosis in these patients was also studied during the last two 
decades. P-selectin is released from platelets and endothelial cells and contributes to the 
adhesion of leucocytes on activated platelets and thrombus formation and to adhesion of 
cancer cells to stimulated endothelial cells. Experimental studies that have been done on 
primates suggest that P-selectin inhibition is as effective as low molecular weight heparin in 
promoting thrombus resolution and in preventing re-occlusion (Chen & Geng, 2006). In 
humans elevated levels of P-selectin may be predictive of thromboembolism in patients with 
cancers (Ay et al, 2008).  
A large case-control study of venous thrombosis in patients with cancer found that the 
presence of factor V Leiden or prothrombin 20210A mutation increases by 12 to 17-fold the 
risk of developing thrombosis compared to those with out these modifications (Blom et 
al,2005).  
Activation of endothelium by tumor-derived inflammatory cytokines, which could induce 
expression of various adhesive molecules such as V-CAM and E-selectin may promote the 
thrombotic process in cancer patients (Varki, 2007).  
Thromboembolic events in PC patients are also influenced by particular conditions that 
generally increase the risk of thrombosis such as immobilization, advanced age, 
comorbidities (infections, cardiac or respiratory failure, obesity, etc.), history of venous 
thrombosis (Offord et al, 2004; Echrish et al, 2011). Also, the local effects of a great tumour, 
such as venous compression, that can predispose to an increased risk of thromboembolism 
(Dumitrascu et al, 2010) . 
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Central vein catheterization used for the administration of cancer therapy represents a risk 
factor for thrombosis in these patients. Patients with distant metastases have more increased 
risk for thrombosis in absence of antithrombotic prophylaxis. The incidence of clinically 
overt venous thrombosis in cancer patients with central venous catheter ranges from 0.3% to 
28%, and rises to 27% - 66% when the diagnosis was assessed by venography (Verso & 
Agnelli, 2003; Verso et al, 2008).  
Chemotherapy has been shown to be an independent risk factor for thrombosis in cancer 
patients. In a large population based study, the risk of thrombosis was increased 6.5 fold in 
patients receiving chemotherapy and 4,1 fold in patients with cancer not receiving this kind 
of therapy, compared to patients without malignancies (Heit et al, 2000, Kirwan et al, 2011). 
The risk is additionally increased if chemotherapy is combined with steroids (Shen et al, 
2011) or erythropoietin (Bennet et al, 2008). The inhibitors of angiogenesis (thalidomide, 
lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) used as novel antineoplasic 
therapy are associated with an increase in arterial and venous thromboembolism and 
hemorrhage (Zangari et al, 2009). Gemcitabine is a deoxycytidine analogue related to 
cytarabine, that has been shown to improve evolution in patients with advanced PC. Deep 
venous thrombosis was found in one study in 3.2% of patients treated with gemcitabine 
(Kaye,1994).  
4. Clinical outcome in pancreatic cancer patients with thrombosis 
Patients with PC may present with signs of venous or arterial thrombosis. Venous 
thrombosis is more frequent and it can affect peripheral or visceral veins (Blom et al, 2006). 
Migratory superficial thrombophlebitis is highly suggestive for a malignancy (Fig. 1). Of the 
visceral vein thrombosis portal thrombosis has a very high incidence. In one study portal 
vein thrombosis was found in 32 of 108 patients (30%) and it was associated with a poor 
prognosis (Price et al, 2010). Perpancreatic veins may also be involved (Fig.2). 
The diagnosis is suggested by clinical signs and is usually confirmed ultrasonographically 
(Fig. 3 and 4).  
Disseminated intravascular coagulation is another coagulation disturbance described in 
PC. It was associated with an increase in circulating TF (Ueda, 2001). This complication 
was also observed in patients suffering from metastatic pancreatic cancer treated with a 
recombinant adenoviral vector containing the cloned human wild type p53 suppressor 
gene (Haag, 2000).  
It is generally reported that patients with cancer and thrombotic complications have a poor 
prognosis (Levitan et al, 1999; Sorensen et al, 2000). In the retrospective study by Epstein 
and colab., 24% of patients with PC and thromboembolism, experienced pulmonary 
embolism. The authors found a reduced overall survival for patients with a thromboembolic 
event (12.9 month) if compared to those without (13.4 month). Treatment consisted of low 
molecular weight heparin, in 95% of patients and inferior vena cava filter was necessary in 
19%. Patients with occult thrombotic events or with thrombosis diagnosed at the time of 
cancer diagnosis, had a poorer survival (6.2 month) compared with those with secondary 
thrombotic events (13.7 month) (Epstein et al, 2010; Shah& Saif, 2010).  
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Fig. 1. Migratory superficial thrombophlebitis in a case of PC (hematoxylin-eosin staining of 
superficial veins) 
 
Fig. 2. Vascular invasion of PC with local vein thrombosis (hematoxylin-eosin staining) 
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Fig. 3. Thrombosis of peroneal vein in a patient with PC (2D and colour Doppler 
echographic examination)  
 
Fig. 4. Thombosis of femoral vein in a patient with PC (2D echographic examination)  
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Looking for possible predictors of thromboembolism in pancreatic cancer, one previous 
study showed that higher levels of TF expression in tumor cells were associated with nearly 
4 fold increase in venous thrombosis (Khorana et al, 2007). In a recent retrospective study 
that included patients diagnosed with pancreaticobiliary cancers between January 2005 and 
December 2008, looked for the association of TF with thromboembolism and survival. This 
study included 117 patients with a median age of 65 years of which 68% had pancreatic 
cancer and 29% biliary cancers. Thrombotic complications were found in 52 (44.4%) patients. 
Elevated levels of TF (greater than 2.5pg/ml) were associated with thromboembolic events 
(odds ratio=1.22;p=0.04). Also, TF levels were predictive for a worse overall survival 
(hazard ratio=1.05; p=0.01) (Barthuar et al, 2010). These results if confirmed in prospective 
studies suggest that TF expressed by neoplastic cells or plasma levels of TF could be used as 
independent predictive biomarkers for thromboembolic events in PC patients and also in 
other cancers (Khorana et al,2007; Barthuar et al, 2010). 
5. Prevention and treatment of thromboembolism in PC  
5.1 Prophylaxis of venous trombosis  
Epidemiologic and pathogenic data clearly indicate that patients with malignancy had an 
important risk of thormboembolic events. In practice, risk stratification can be used to 
classify patients according to their thrombotic risk. The ACCP guidelines consider the 
patient with cancer in the very high risk category particularly when surgery is 
recommended. Other factors that may increase patient’s risk are age, immobilization, prior 
history of venous thrombosis, obesity and central venous catheter (Geerts et al, 2004; Caprini 
et al, 2001).  
Prophylaxis in cancer is indicated mainly in two distinct situations: in patients undergoing 
surgery and in medical patients receiving chemotherapy.  
Patients undergoing abdominal surgery are a particularly high-risk population who may 
benefit for extended thromboprophylaxis. Low molecular weight heparins are preferred as 
they showed to be as effective and safe as unfractionated heparin. Several studies showed a 
reduction in thromboembolic complications in patients receiving prolonged prophylaxis for 
3 or 4 weeks compared to those with 1 week of treatment in postoperative period. This 
beneficial effect was not accompaneied by an increase in hemorrhagic complications 
(Bergqvist et al, 2002; Rasmussen et al, 2003).  
In patients treated with chemotherapy antithrombotic prophylaxis showed also a reduction 
in thromboembolic risk. There are 2 trials in patients with PC treated with gemcitabine and 
a low molecular weight heparin and another one in wich a low molecular weight heparin 
was associated to a combined chemotherapy gemcitabine and cisplatinum.  
The results of the Charité Onkologie (CONKO)-004 trial were recently published. The 
principal objective of this trail was the evaluation of the reduction in symptomatic 
thromboembolic events in patients with advanced PC. The second end point was the overall 
survival. Between April 2004 and January 2009, 312 patients with histological confirmed 
advanced PC were randomized into two groups as follows: 160 patients received treatment 
with enoxaparin 1 mg/kg once a day for 3 month, followed by 40 mg daily and 152 did not 
receive antithrombotic prophylaxis. The results indicated a significant reduction of 
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symptomatic thromboembolism in treated patients after 3 month (1.25% compared to 9.87% 
in non treated patients). This significant difference was also found after 12 months with an 
incidence of 5% in treated patients compared to 15.13% in non treated arm of the trial. There 
were no significant major hemorrhagic complications in both groups. The median overall 
survival was not different between the two groups (9.92 month in treated patients versus 
8.15 month in no treatment group; p=0.054), for a median follow up period of 45.44 months 
(Reiss et al, 2010).  
In the FRAGEM (Chemotherapy With or Without Dalteparin) trial, 123 patients were 
randomised to receive dalteparin. This study showed also a significant reduction in 
thromboembolic events in patients receiving prophylaxis (Maraveyas et al, 2007).  
The third trial aimed to assess the effects of the addition of low molecular weight heparin 
(nadoparin) to gemcitabine plus cisplatinum combination in 42 patients with advanced PC. 
The results showed a better mean time to progression in the group receiving prophylaxis 
(6.0+/-0.9 months) when compared to control group (3.0+/-1.5 months) (p=0.0001). Also 
median overall survival time for the nadoparin group was 9.0+/-1.9 months compared to 
4.0+/-0.4 months (p=0.0034) in the control group (Icli et al, 2007).  
The results of these trials showed that the association of a low molecular weight heparin to 
chemotherapy in advanced pancreatic cancer patients reduces the risk of thromboembolic 
events. However, the CONKO-004 did not found any improvement in the overall survival 
and time to progression. This needs to be verified in future prospective trials.  
In patients with central vein catheter used commonly for the administration of 
chemotherapeutic agents and parenteral nutrition, anticoagulation is not recommended for 
routine prophylaxis of catheter related thrombosis in cancer patients (Geerts et al, 2004). 
Even if early studies showed risk of venous thrombosis related to central vein catheters 
(Montreal et al, 1996), a large multinational trial that investigated the efficacy of dalteparin 
in preventing catheter related thrombosis, found that the risk of thrombosis was not 
significantly different in the group treated with dalteparin compared to placebo-treated 
patients (Karthaus et al, 2006). Prophylaxis in patients with central vein catheters may be 
imposed sometimes when additional risk factors are detected.  
5.2 Treatment of venous thrombosis 
Treatment of venous thombotic complications in patients with cancer is usually difficult due 
to the risk of recurrences and at the same time of bleeding with severe consequences. The 
aims of treatment are reduction of clinical manifestations of thrombosis and of the risks 
pulmonary embolism and postthrombotic syndrome.  
The treatment of choice is the administration of a low molecular weight heparin for one 
week followed by an oral anticoagulant (vitamin K antagonist). Low molecular weight 
heparins have been shown to be as effective and save as unfractionated heparin. They are 
preferred like first line treatment because usually no laboratory monitoring is necessary, and 
the risks of developing heparin induced thrombocytopenia and osteoporosis is reduced. 
Also the administration of this type of heparin is convenient using once or twice daily doses 
as subcutaneous injection (Dolovich et al, 2000; van den Belt et al, 2000, Er &Zacharski, 
2006).  
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Recurrent thrombosis needs long-term management. In cancer patients prolonged anti 
thrombotic, particularly with oral antivitamin K medication, is associated with increased 
risk of hemorrhagic complications that may be linked to malnutrition, liver dysfunction and 
metastases, reduced alimentary intake or vomiting. The risk of bleeding appears to correlate 
with the extent of the disease. In a study that investigated the risk of bleeding in patients 
with different extent of the disease, patients with moderately extensive cancer had a 2-3-fold 
increase in risk of major bleeding; patients with extensive cancer had a 5-fold increase in this 
risk (Prandoni et al, 2002).  
Low molecular weight heparins are now preferred as long term secondary prevention 
treatment in these patients. This indication is based on the results of several randomized 
trials that showed a superior efficacy and safety of low molecular weight heparins 
compared with oral anticoagulants in long term administration. In a multicenter 
randomized trial patients were treated for 3 month with enoxaparin or with warfarin. Of the 
group receiving warfarin 15 (21%) of 71 patients had a major bleeding or a thrombotic 
recurrence, compared to 7 (10.5%) of 67 patients treated with enoxaparin (Meyer et al, 2002). 
A large multicenter trail, „The Randomized Comparison of Low–Molecular-Weight Heparin 
versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous 
Thromboembolism in Patients with Cancer (CLOT) compared treatment with dalteparin 
with oral anticoagulant therapy. After 6 months of treatment the probability of recurrent 
venous thrombosis was 17% in patients receiving oral anticoagulation compared to 9% in 
those treated with dalteparin. There were no significant differences between groups for the 
hemorrhagic complications (Lee et al, 2003).  
5.3 Antineoplastic effects of anticoagulants 
There are evidences that anticoagulant therapy may have also anticancer effects. Heparins in 
addition to activation of antithrombin, may promote the release of the tissue factor pathway 
inhibitor from the endothelium that blocks tissue factor expressed by tumor cells (Alban, 2001; 
Sandset et al, 2001). Heparin is also able to bind to and to inhibit some inflammatory cytokines 
that can activate endothelial cells and increase expression of adhesion molecules (Elsayed & 
Becker, 2003; Varki ,2007). Heparin may interfere with formation of the platelet "cloak" around 
tumor cells suggesting a possible effect in metastasis prevention (Borsig et al, 2001).  
Several clinical studies support the efficacy of heparins in improuving tumor response and 
survival. The administration of nadroparin in patients with advanced solid cancers 
increased median survival to 8 month compared to 6.6 months in patients receiving placebo, 
after 6 weeks of treatment (Klerk et al, 2005). Dalteparin associated in the treatemnt of 
patients with small cell lung cancer, for 18 weeks improved tumor response and median 
overall survival from 8 to 13 months (Altinbas et al, 2004).  
Beneficial effects have also been reported for warfarin in cancer patients. A prospective 
randomized trial showed that survival of patients with small-cell lung carcinoma had a 
significant prolonged survival if warfarin was added to standard therapy. The median 
survival and the time to first evidence of disease progression were increased in patients 
receiving warfarin (Zacharski et al, 1981). 
Data suggesting the participation of coagulation mechanisms in tumour growth are important 
arguments for researchers to explore this novel therapeutic strategy in cancer patients.  
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6. Conclusions  
Pancreatic cancer is associated with a very increased risk of thromboembolic events. The 
mechanisms underlying this association are complex and multifactorial but are not yet 
clearly understood. Thromboembolic complications in patients with PC indicate a poor 
prognosis and a reduction of life expectancy. Antithrombotic prophylaxis in advanced PC 
treated with chemotherapy reduces the risk of embolic complications and it may also 
improve survival and time to progression of cancer in these patients. The medication of 
choice in preventing and treating thrombosis are low molecular weight heparins. 
Anticoagulant therapy may help cancer patients due also to a possible antitumor effect. 
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